Skip to main content
Clinical Trials/CTRI/2018/10/016215
CTRI/2018/10/016215
Not yet recruiting
未知

An observation study to assess safety and efficacy of Tablet NGfenceTM 2.6/6.4 mg (Controlled Release) in patients with Angina

Care Lifescience Private Limited0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Care Lifescience Private Limited
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Care Lifescience Private Limited

Eligibility Criteria

Inclusion Criteria

  • 1Patients with Normal Sinus Rhythm on ECG at Screening
  • 2Patients who have signed Written Informed Consent
  • 3Patients with stable/unstable or Prinzmetals angina for at least 3 months prior to inclusion (mild/moderate/severe)
  • 4Male or Female patients \> 18 years and \< 75 years of age.

Exclusion Criteria

  • 1Male or Female patients \< 18 years and \> 75 years of age
  • 2Congestive heart failure stage III or IV NYHA.
  • 3Symptomatic hypotension.
  • 4Atrial fibrillation, flutter, pacemaker or cardioverter\-defibrillator implantation
  • 5History of serious abnormal drug reaction.
  • 6Patients with Postural hypotension
  • 7Patients with chronic kidney failure
  • 8History of any serious infectious disease like Hepatitis B or C, HIV etc.
  • 9History of severe psychiatric or behavioral disorders likely to interfere with the study.
  • 10Patients with other severe disease likely to interfere with the study in the investigators judgment.

Outcomes

Primary Outcomes

Not specified

Similar Trials